{"article_title": "Drug company gets U.S. subpoenasMedCity News", "article_keywords": ["firm", "business", "healthcare", "wall", "company", "million", "drug", "chief", "health", "closed", "subpoenasmedcity", "valeant", "gets", "price"], "article_url": "http://medcitynews.com/2015/10/latest-valeant-news/", "article_text": "TOP STORIES\n\nEmbattled Valeant Pharmaceuticals International said it has received subpoenas from U.S. attorneys in Massachusetts and New York relating to its patient assistance programs. That isn\u2019t the only latest Valeant news: It also wrote in a letter to Congress that \u201cthere was considerable room to increase the price of both drugs without unduly depleting the funds available to the hospitals from payers.\u201d \u2014 Reuters, Wall Street Journal & PR Newswire\n\nFascinating piece on Theranos, which apparently doesn\u2019t use its own technology for all of its tests. \u2013 Wall Street Journal\n\nGenetic testing has busted the $100 barrier, as Huntsville, Alabama-based Kailos Genetics has debuted a full-panel test called PGxComplete. It will be available for the introductory price of $99 through November 30, down from the regular price of $299, the company said. \u201cIt\u2019s our goal to give people the ability to understand how medicine will work for them before it is prescribed,\u201d Kailos Chief Scientific Officer Troy Moore said. \u2014 WAAY-TV, Business Wire\n\nLIFE SCIENCES\n\nBristol-Myers Squibb signed a cancer licensing deal with Five Prime Therapeutics worth up to $1.74 billion. \u2013 Reuters\n\nBritish biotech entrepreneurs are worried the sector could be squeezed as the British government looks for savings after a relative public spending boom on the life sciences. \u2013 Financial Times\n\nEli Lilly said that baricitinib, its experimental pill for rheumatoid arthritis, has proven more effective in a clinical trial than Abbvie blockbuster injectable Humira. \u2014 Reuters\n\nThe FDA has rejected Pfizer\u2019s request to approve RA drug Xeljanz for treating plaque psoriasis. \u2014 Reuters\n\nA former University of Pennsylvania cancer researcher has been sentenced to a year in prison for misdirecting federal grant money into his own business. \u2014 Philadelphia Business Journal\n\nCancer-focused biotech firm Galera Therapeutics has completed a $37 million Series B round. \u2014 Business Wire\n\nRosetta Genomics has closed on an $8 million private placement. \u2014 Business Wire\n\nDr. Eric Topol has yet another title for his CV: board member of biopharmaceutical startup MyoKardia. \u2014 Business Wire\n\nViamet Pharmaceuticals has hired Dr. Oren Cohen as chief medical officer, plucking Cohen from Quintiles. \u2014 Business Wire\n\nPAYERS-PROVIDERS\n\nAre chief information security officers \u201chealthcare\u2019s new rock stars\u201d? \u2014 Healthcare IT News\n\nJim Roosevelt, CEO of Tufts Health Plan in Massachusetts and grandson of President Franklin Delano Roosevelt, will leave his post Jan. 1. \u2014 Boston Business Journal\n\nTECHNOLOGY\n\nA new study suggests that remote home monitoring and other telemedicine services can reduce hospitalizations and emergency visits. \u2014 mHealth Intelligence\n\nPrivate investment firm Platinum Equity is selling mobile diagnostic imaging firm DMS Health to larger competitor Digirad for an undisclosed sum. \u2014 PE Hub\n\nVerisk Analytics has retained Morgan Stanley to sell off its healthcare division. \u2014 The Deal\n\nAs many as 850,000 retail pharmacies in India closed their doors Wednesday in a one-day protest against online pharmacies. \u2014 Reuters\n\nPOLITICS\n\nTennessee\u2019s health co-op has shut down \u2013 the sixth Obamacare co-op this year. \u2013 The Hill\n\nA nice look at how Jeb Bush\u2019s healthcare reform plan could change health IT strategies. \u2013 Becker\u2019s Hospital Review\n\nMassachusetts\u2019 health care regulators will begin notifying insurers and providers being flagged for excessive cost growth. \u2013 Boston Business Journal\n\nOpenGov, a startup that wants to change how governments analyze and share financial data, closed $25 million. \u2013 VentureBeat\n\nA LITTLE BIT EXTRA\n\nWarning: clickbait ahead. Ansell Healthcare Products, maker of Skyn condoms, is suing Reckitt Benckiser for patent infringement, alleging that Reckitt\u2019s Durex RealFeel condom violates the latter\u2019s intellectual property for \u201cDip-formed Synthetic Polyisoprene Latex Articles with Improved Intraparticle and Interparticle Crosslinks.\u201d That\u2019s a decidedly unsexy way of saying the item in question doesn\u2019t contain latex. \u2014 PR Newswire\n\nPhoto:\n\n", "article_metadata": {"description": "Also, a sixth Obamacare co-op had failed, Bristol-Myers Squibb inks a $1.7 billion cancer licensing deal, and learn how Jeb Bush's healthcare reform would impact health IT.", "generator": "WordPress 4.5.2", "og": {"site_name": "MedCity News", "description": "Also, a sixth Obamacare co-op had failed, Bristol-Myers Squibb inks a $1.7 billion cancer licensing deal, and learn how Jeb Bush's healthcare reform would impact health IT.", "title": "Morning Read: Valeant gets its subpoenas, Theranos doesn\u2019t use its own tech, gene testing breaks $100 barrier", "locale": "en_US", "image": "http://medcitynews.com/wp-content/uploads/2015/09/valeant.jpg", "updated_time": "2015-10-15T07:56:49-04:00", "url": "http://medcitynews.com/2015/10/latest-valeant-news/", "type": "article"}, "twitter": {"image": "http://medcitynews.com/wp-content/uploads/2015/09/valeant.jpg", "creator": "@nversel", "description": "Also, a sixth Obamacare co-op had failed, Bristol-Myers Squibb inks a $1.7 billion cancer licensing deal, and learn how Jeb Bush's healthcare reform would impact health IT.", "card": "summary", "title": "Latest Valeant news: Drug company gets U.S. subpoenas"}, "robots": "noodp", "fb": {"app_id": 148725768475669}, "google-site-verification": "xudQg7nxVR9ifmMTY4Tf-0wVtX9b6rWLQd0utCweGOc", "keywords": "weight loss, obesity, overweight,diabetes,massachusetts,medical devices,obesity,startups,healthcare innovation, medcity news,medcity news,san francisco, startups, life sciences,accelerator,rock health,startup advice,startup funding,patient monitoring system, motion sensors ,dc,healthcare it,washington,foodborne pathogens, diagnostics company, diagnostic platforms,minimally invasive surgery, laser surgery,cambridge,dealflow,hospitals,wellpoint, healthways, health and wellness, employee wellness programs,investing,wellness,medtronic, shanghai innovation center, china, r&d,china,mdt,minneapolis,minnesota,publics,twin cities,ulcerative colitis, abbott labs, humira,abbott labs,doctors,pharmaceuticals,skin disorders, pharmaceuticals, md anderson cancer center,cancer,texas,renal denervation, st. jude medical,st. jude medical,stj,emr, ehr, electronic health records, electronic medical records, certified emr,certified emr,ehr,electronic health records,electronic medical records,advanced cellular technology,amyotrophic lateral sclerosis,embryonic stem cells,geron corporation,lou gehrig\\'s disease,macular degeneration,regenerative medicine,spinal cord damage,value-based healthcare system, obamacare, fee-for-service model,california,cleveland,health insurance,insurance,ohio,pennsylvania,politics,cancer treatment options library, aetna, aet, healthcare it,aet,aetna,health it,phi,philadelphia,genetic testing, Kailos Genetics, Theranos, Valeant Pharmaceuticals, , MedCity News", "article": {"section": "Daily", "tag": "Valeant Pharmaceuticals", "published_time": "2015-10-15T07:55:47-04:00", "modified_time": "2015-10-15T07:56:49-04:00"}, "viewport": "width=device-width,initial-scale=1.0,width=device-width,user-scalable=no,minimum-scale=1.0,maximum-scale=1.0"}, "_id": "\"57477af46914bd0286fdd06e\"", "article_summary": "It will be available for the introductory price of $99 through November 30, down from the regular price of $299, the company said.\n\u2014 mHealth IntelligencePrivate investment firm Platinum Equity is selling mobile diagnostic imaging firm DMS Health to larger competitor Digirad for an undisclosed sum.\n\u2013 Boston Business JournalOpenGov, a startup that wants to change how governments analyze and share financial data, closed $25 million.\n\u2013 Wall Street JournalGenetic testing has busted the $100 barrier, as Huntsville, Alabama-based Kailos Genetics has debuted a full-panel test called PGxComplete.\n\u2014 ReutersThe FDA has rejected Pfizer\u2019s request to approve RA drug Xeljanz for treating plaque psoriasis."}